Related references
Note: Only part of the references are listed.Iloperidone, asenapine and lurasidone: a primer on their current status
Frank I. Tarazi et al.
EXPERT OPINION ON PHARMACOTHERAPY (2012)
Asenapine as Adjunctive Treatment for Acute Mania Associated With Bipolar Disorder Results of a 12-Week Core Study and 40-Week Extension
Armin Szegedi et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2012)
Asenapine effects on cognitive and monoamine dysfunction elicited by subchronic phencyclidine administration
John D. Elsworth et al.
NEUROPHARMACOLOGY (2012)
Effects of asenapine on depressive symptoms in patients with bipolar I disorder experiencing acute manic or mixed episodes: a post hoc analysis of two 3-week clinical trials
Armin Szegedi et al.
BMC PSYCHIATRY (2011)
The role of serotonin receptors in the action of atypical antipsychotic drugs
H. Y. Meltzer et al.
CURRENT OPINION IN PHARMACOLOGY (2011)
Attenuation of chronic mild stress-induced 'anhedonia' by asenapine is not associated with a 'hedonic' profile in intracranial self-stimulation
Hugh M. Marston et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2011)
Pharmacological Blockade of 5-HT7 Receptors as a Putative Fast Acting Antidepressant Strategy
Ouissame Mnie-Filali et al.
NEUROPSYCHOPHARMACOLOGY (2011)
Asenapine improves phencyclidine-induced object recognition deficits in the rat: evidence for engagement of a dopamine D1 receptor mechanism
Shikha Snigdha et al.
PSYCHOPHARMACOLOGY (2011)
The FDA-NIMH-MATRICS Guidelines for Clinical Trial Design of Cognitive-Enhancing Drugs: What Do We Know 5 Years Later?
Robert W. Buchanan et al.
SCHIZOPHRENIA BULLETIN (2011)
Effects of asenapine, olanzapine, and risperidone on psychotomimetic-induced reversal-learning deficits in the rat
Samantha L. McLean et al.
BEHAVIOURAL BRAIN RESEARCH (2010)
Therapeutic Options for Treatment-Resistant Depression
Richard C. Shelton et al.
CNS DRUGS (2010)
Repeated effects of asenapine on adrenergic and cholinergic muscarinic receptors
Yong Kee Choi et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2010)
Lu AE58054, a 5-HT6 antagonist, reverses cognitive impairment induced by subchronic phencyclidine in a novel object recognition test in rats
Jorn Arnt et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2010)
Efficacy and Safety of Asenapine in a Placebo- and Haloperidol-Controlled Trial in Patients With Acute Exacerbation of Schizophrenia
John M. Kane et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2010)
Asenapine induces differential regional effects on serotonin receptor subtypes
F. I. Tarazi et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2010)
Animal models of cognitive dysfunction and negative symptoms of schizophrenia: Focus on NMDA receptor antagonism
Joanna C. Neill et al.
PHARMACOLOGY & THERAPEUTICS (2010)
Sertindole improves sub-chronic PCP-induced reversal learning and episodic memory deficits in rodents: involvement of 5-HT6 and 5-HT2A receptor mechanisms
Nagi Idris et al.
PSYCHOPHARMACOLOGY (2010)
INVESTIGATION INTO COGNITIVE FUNCTION IN FIRST EPISODE PSYCHOSIS PATIENTS
Majid M. Saleem et al.
SCHIZOPHRENIA RESEARCH (2010)
The Serotonin-1A Receptor in Anxiety Disorders
Elena Akimova et al.
BIOLOGICAL PSYCHIATRY (2009)
Electrophysiological characterization of the effects of asenapine at 5-HT1A, 5-HT2A, α2-adrenergic and D2 receptors in the rat brain
Ramez Ghanbari et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2009)
D1-like receptor activation improves PCP-induced cognitive deficits in animal models: Implications for mechanisms of improved cognitive function in schizophrenia
Samantha L. McLean et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2009)
Asenapine: a novel psychopharmacologic agent with a unique human receptor signature
M. Shahid et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2009)
5-HT1A receptor function in major depressive disorder
Jonathan Savitz et al.
PROGRESS IN NEUROBIOLOGY (2009)
Asenapine restores cognitive flexibility in rats with medial prefrontal cortex lesions
David S. Tait et al.
PSYCHOPHARMACOLOGY (2009)
Asenapine effects in animal models of psychosis and cognitive function
Hugh M. Marston et al.
PSYCHOPHARMACOLOGY (2009)
Asenapine Exerts Distinctive Regional Effects on Ionotropic Glutamate Receptor Subtypes in Rat Brain
Frank I. Tarazi et al.
SYNAPSE (2009)
ASENAPINE MALEATE: A NEW DRUG FOR THE TREATMENT OF SCHIZOPHRENIA AND BIPOLAR MANIA
Frank I. Tarazi et al.
DRUGS OF TODAY (2009)
Improvement of phencyclidine-induced social behaviour deficits in rats:: Involvement of 5-HT1A receptors
Shikha Snigdha et al.
BEHAVIOURAL BRAIN RESEARCH (2008)
Selective Histamine H1 Antagonism: Novel Hypnotic and Pharmacologic Actions Challenge Classical Notions of Antihistamines
Stephen M. Stahl
CNS SPECTRUMS (2008)
Glutamatergic dysfunction in schizophrenia: From basic neuroscience to clinical psychopharmacology
Rodrigo D. Paz et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2008)
A randomized, double-blind comparison of clozapine and high-dose olanzapine in treatment-resistant patients with schizophrenia
Herbert Y. Meltzer et al.
JOURNAL OF CLINICAL PSYCHIATRY (2008)
Muscarinic receptors: do they have a role in the pathology and treatment of schizophrenia?
Elizabeth Scarr et al.
JOURNAL OF NEUROCHEMISTRY (2008)
Asenapine increases dopamine, norepinephrine, and acetylcholine efflux in the rat medial prefrontal cortex and hippocampus
Mei Huang et al.
NEUROPSYCHOPHARMACOLOGY (2008)
Differential regional and dose-related effects of asenapine on dopamine receptor subtypes
Frank I. Tarazi et al.
PSYCHOPHARMACOLOGY (2008)
Asenapine, a novel psychopharmacologic agent:: preclinical evidence for clinical effects in schizophrenia
Olivia Franberg et al.
PSYCHOPHARMACOLOGY (2008)
Efficacy and tolerability of asenapine in acute schizophrenia: A placebo- and risperidone-controlled trial
Steven G. Potkin et al.
JOURNAL OF CLINICAL PSYCHIATRY (2007)
Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: A randomized, double-blind 52-week comparison
Richard S. E. Keefe et al.
AMERICAN JOURNAL OF PSYCHIATRY (2007)
Actions of novel antipsychotic agents on apomorphine-induced PPI disruption:: Influence of combined serotonin 5-HT1A receptor activation and dopamine D2 receptor blockade
Agnes L. Auclair et al.
NEUROPSYCHOPHARMACOLOGY (2006)
Involvement of 5-HT1A receptors in prefrontal cortex in the modulation of dopaminergic activity:: Role in atypical antipsychotic action
L Díaz-Mataix et al.
JOURNAL OF NEUROSCIENCE (2005)
Contrasting contribution of 5-hydroxytryptamine 1A receptor activation to neurochemical profile of novel antipsychotics:: Frontocortical dopamine and hippocampal serotonin release in rat brain
MB Assié et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2005)
Serotonin 5-HT2C receptors as a target for the treatment of depressive and anxious states:: Focus on novel therapeutic strategies
MJ Millan
THERAPIE (2005)
Neurobiology of executive functions: Catecholamine influences on prefrontal cortical functions
AFT Arnsten et al.
BIOLOGICAL PSYCHIATRY (2005)
Treatment of cognitive dysfunction in schizophrenia
J Peuskens et al.
CLINICAL THERAPEUTICS (2005)
Effects of the novel antidepressant milnacipran in a chronic mild stress model of depression
M Papp et al.
DRUG DEVELOPMENT RESEARCH (2004)
Alpha2-adrenoceptor mediated co-release of dopamine and noradrenaline from noradrenergic neurons' in the cerebral cortex
P Devoto et al.
JOURNAL OF NEUROCHEMISTRY (2004)
Metabolic risk during antipsychotic treatment
JW Newcomer
CLINICAL THERAPEUTICS (2004)
Adrenergic targets for the treatment of cognitive deficits in schizophrenia
AFT Arnsten
PSYCHOPHARMACOLOGY (2004)
Targeting the dopamine D1 receptor in schizophrenia:: insights for cognitive dysfunction
PS Goldman-Rakic et al.
PSYCHOPHARMACOLOGY (2004)
α-adrenoceptor modulation hypothesis of antipsychotic atypicality
TH Svensson
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2003)
Serotonin receptors : their key role in drugs to treat schizophrenia
HY Meltzer et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2003)
Reboxetine modulates norepinephrine efflux in the frontal cortex of the freely moving rat:: the involvement of α2 and 5-HT1A receptors
JCE Owen et al.
NEUROSCIENCE LETTERS (2003)
Long-term effects of olanzapine, risperidone, and quetiapine on serotonin 1A, 2A and 2C receptors in rat forebrain regions
FI Tarazi et al.
PSYCHOPHARMACOLOGY (2002)
Atypical, but not typical, antipsychotic drugs increase cortical acetylcholine release without an effect in the nucleus accumbens or striatum
J Ichikawa et al.
NEUROPSYCHOPHARMACOLOGY (2002)
Effects of newer Antipsychotics on extrapyramidal function
D Tarsy et al.
CNS DRUGS (2002)
Dopamine D2 receptor occupancy is a common mechanism underlying animal models of antipsychotics and their clinical effects
MLG Wadenberg et al.
NEUROPSYCHOPHARMACOLOGY (2001)
The emerging role of glutamate in the pathophysiology and treatment of schizophrenia
DC Goff et al.
AMERICAN JOURNAL OF PSYCHIATRY (2001)
Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review
MA Geyer et al.
PSYCHOPHARMACOLOGY (2001)
A novel augmentation strategy for treating resistant major depression
RC Shelton et al.
AMERICAN JOURNAL OF PSYCHIATRY (2001)
Interactions between monoamines, glutamate, and GABA in schizophrenia: New evidence
A Carlsson et al.
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY (2001)
Serotonin model of schizophrenia: emerging role of glutamate mechanisms
GK Aghajanian et al.
BRAIN RESEARCH REVIEWS (2000)
Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex
W Zhang et al.
NEUROPSYCHOPHARMACOLOGY (2000)
Antidepressant-like activity of amisulpride in two animal models of depression
M Papp et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2000)
Share Paper
